Bellus Health Net Income 2006-2021 | BLU

Bellus Health net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Bellus Health Annual Net Income
(Millions of US $)
2020 $-32
2019 $-26
2018 $-7
2017 $-1
2016 $-2
2015 $0
2014 $-2
2013 $-1
2012 $-13
2011 $3
2010 $-20
2009 $-8
2008 $-48
2007 $-81
2006 $-65
2005 $-62
Bellus Health Quarterly Net Income
(Millions of US $)
2021-09-30 $-23
2021-06-30 $-18
2021-03-31 $-16
2020-12-31 $-7
2020-09-30 $-6
2020-06-30 $-8
2020-03-31 $-10
2019-12-31 $-10
2019-09-30 $-7
2019-06-30 $-6
2019-03-31 $-4
2018-12-31 $-3
2018-09-30 $-2
2018-06-30 $-1
2018-03-31 $-0
2017-12-31 $-1
2017-09-30 $-1
2017-06-30 $0
2017-03-31 $1
2016-12-31 $-0
2016-09-30 $-0
2016-06-30 $-0
2016-03-31 $-1
2015-12-31 $1
2015-09-30 $-0
2015-06-30 $-0
2015-03-31 $-0
2014-12-31 $0
2014-09-30 $-1
2014-06-30 $-1
2014-03-31 $-1
2013-12-31 $-0
2013-09-30 $1
2013-06-30 $-1
2013-03-31 $-1
2012-12-31 $-0
2012-09-30 $-0
2012-06-30 $-9
2012-03-31 $-3
2011-12-31 $-2
2011-09-30 $0
2011-06-30 $2
2011-03-31 $3
2010-12-31 $-4
2010-09-30 $-6
2010-06-30 $-6
2010-03-31 $-4
2009-12-31 $-5
2009-09-30 $-6
2009-06-30 $13
2009-03-31 $-10
2008-12-31 $-12
2008-09-30 $-11
2008-06-30 $-13
2008-03-31 $-13
2007-12-31 $-16
2007-09-30 $-14
2007-06-30 $-32
2007-03-31 $-21
2006-12-31 $-17
2006-09-30 $-17
2005-12-31 $-13
2005-09-30 $-18
2005-06-30 $-15
2005-03-31 $-13
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.412B $0.000B
BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90